CL2020002369A1 - Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina - Google Patents

Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina

Info

Publication number
CL2020002369A1
CL2020002369A1 CL2020002369A CL2020002369A CL2020002369A1 CL 2020002369 A1 CL2020002369 A1 CL 2020002369A1 CL 2020002369 A CL2020002369 A CL 2020002369A CL 2020002369 A CL2020002369 A CL 2020002369A CL 2020002369 A1 CL2020002369 A1 CL 2020002369A1
Authority
CL
Chile
Prior art keywords
lactalbumin
pharmaceutical
alpha
food
food supplement
Prior art date
Application number
CL2020002369A
Other languages
English (en)
Inventor
Paolo Mainardi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020002369A1 publication Critical patent/CL2020002369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparación farmacéutica o de complemento alimenticio que incluye alfa-lactoalbúmina y al menos un ácido graso de cadena corta (SCFA) o un precursor o derivado del mismo para uso en el tratamiento de trastornos del sistema nervioso central; el SCFA o su precursor o derivado puede estar contenido en al menos una primera unidad de dosificación junto con un portador aceptable desde el punto de vista farmacéutico o alimentario y la alfa-lactoalbúmina en al menos una segunda unidad de dosificación junto con un portador aceptable desde el punto de vista farmacéutico o alimentario, y dichas unidades de dosificación pueden ser unidades distintas pretendidas para administración simultánea o separada o la preparación puede consistir en una composición farmacéutica o de complemento alimenticio que comprende dicho al menos un ácido graso de cadena corta o un precursor o derivado del mismo y alfa- lactoalbúmina juntos con un portador aceptable desde el punto de vista farmacéutico o alimentario.
CL2020002369A 2018-03-14 2020-09-14 Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina CL2020002369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000003557A IT201800003557A1 (it) 2018-03-14 2018-03-14 Preparazione farmaceutica o di integratore alimentare a base di alfa-lattoalbumina

Publications (1)

Publication Number Publication Date
CL2020002369A1 true CL2020002369A1 (es) 2021-05-07

Family

ID=62455774

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002369A CL2020002369A1 (es) 2018-03-14 2020-09-14 Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina

Country Status (11)

Country Link
US (1) US11554162B2 (es)
EP (1) EP3764992A1 (es)
JP (1) JP7372269B2 (es)
AU (1) AU2019233637A1 (es)
BR (1) BR112020018533A2 (es)
CA (1) CA3093505A1 (es)
CL (1) CL2020002369A1 (es)
EA (1) EA202092105A1 (es)
IT (1) IT201800003557A1 (es)
MX (1) MX2020009470A (es)
WO (1) WO2019175274A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096870A (en) * 1994-01-05 2000-08-01 Sepragen Corporation Sequential separation of whey
US6884421B2 (en) * 2002-03-27 2005-04-26 Council Of Scientific And Industrial Research Pharmaceutical composition for diabetic nephropathy
JP2006219458A (ja) * 2005-02-14 2006-08-24 Meiji Milk Prod Co Ltd 虚血性腸疾患抑制剤
US20100168233A1 (en) * 2007-02-21 2010-07-01 Power Paper Ltd Terbinafine formulation
WO2008138348A1 (en) * 2007-05-09 2008-11-20 Nya Hamlet Pharma Ab Preparation of complexed lactalbumin
IT1392333B1 (it) * 2008-12-16 2012-02-28 Giofarma S R L Preparazione farmaceutica per il trattamento di patologie depressive, contenente una proteina con elevato rapporto triptofano/lnaa
JP5409808B2 (ja) * 2010-07-02 2014-02-05 森永乳業株式会社 治療薬および治療方法
CN105746711A (zh) * 2014-12-15 2016-07-13 内蒙古蒙牛乳业（集团）股份有限公司 一种改善睡眠的牛奶制品及其制备方法
JP2018537441A (ja) * 2015-11-09 2018-12-20 エム・ジェイ・エヌ ユー．エス． ホールディングス リミテッド ライアビリティー カンパニー Ｌｇｇ並びに食品酪酸塩および／または内因性酪酸塩の形成を刺激するための化合物を含む栄養組成物

Also Published As

Publication number Publication date
BR112020018533A2 (pt) 2020-12-29
JP7372269B2 (ja) 2023-10-31
EA202092105A1 (ru) 2021-02-20
US11554162B2 (en) 2023-01-17
IT201800003557A1 (it) 2019-09-14
AU2019233637A1 (en) 2020-10-22
EP3764992A1 (en) 2021-01-20
US20210361748A1 (en) 2021-11-25
CA3093505A1 (en) 2019-09-19
MX2020009470A (es) 2022-11-03
JP2021517591A (ja) 2021-07-26
WO2019175274A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
Blondeau The nutraceutical potential of omega-3 alpha-linolenic acid in reducing the consequences of stroke
WO2016138030A3 (en) Compositions and methods for tolerizing the immune system to allergens
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
CR7654A (es) Una combinacion de azelatina y esteroides
MX2021004999A (es) Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos.
ES2659353T3 (es) Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer
BR112015022306A2 (pt) adoçante aperfeiçoado
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
AR110060A1 (es) Composiciones nutricionales que proporcionan el manejo dietético de cólicos
AR105237A1 (es) Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico
CL2020002369A1 (es) Preparación farmacéutica o de complemento alimenticio a base de alfa-lactoalbúmina
AR110344A1 (es) Métodos y regímenes de alimentación que comprenden la administración de composiciones nutricionales que contienen butirato dietario
AR069356A1 (es) Tratamiento de disfagia faringea oral
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
PH12018000227B1 (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2017152130A8 (en) Pharmaceutical compositions
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
MX2019004191A (es) Composiciones de alimentos y bebidas que comprenden inhibidores de pde5.
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
RU2012156681A (ru) Средство (варианты), фармацевтическая композиция и способ химиопрофилактики предрака и рака предстательной железы
AR115724A1 (es) Composición farmacéutica que contiene un péptido
AR112799A1 (es) Cápsula